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http://dx.dGraft-versus-Host Disease Induced
Graft-versus-Leukemia Effect: Greater Impact on
Relapse and Disease-Free Survival after Reduced
Intensity Conditioning
Daniel Weisdorf,1,2 Mei-Jie Zhang,2,3 Mukta Arora,1,2 Mary M. Horowitz,2,3
J. Douglas Rizzo,2,3 Mary Eapen2,3We studied graft-versus-host disease (GVHD) on relapse, transplant-related mortality (TRM), disease-free
survival (DFS), and overall survival (OS) after allogeneic transplantation for acute myelogenous leukemia
(AML) (n 5 4224) and myelodysplastic syndrome (MDS) (n 5 1517) in 4 groups: without GVHD, acute
GVHD (aGVHD) alone, chronic GVHD (cGVHD) alone, and aGVHD 1 cGVHD. Examining GVHD as
a time-dependent covariate, after myeloablative conditioning (MAC), cGVHD and aGVHD 1 cGVHD were
associated with lower relapse (P\ .002). TRM was higher in all GVHD groups (P\ .0001); DFS and OS
were lowerwith aGVHD6 cGVHD(P\.0001).After reduced-intensity conditioning (RIC), relapsewas lower
in allGVHDgroups (P\.0001); TRMwas increased andDFS andOSwere reducedwith anyGVHD(P\.0001).
In those surviving disease-free ($1-year) after MAC, relapse risks were similar in all groups and TRM was
higher with any GVHD (P\ .0001). DFS and OS were lower with cGVHD and aGVHD 1 cGVHD (P\
.0006). After RIC, relapse was lower (P 5 .009) and TRM higher (P 5 .002) only with aGVHD 1 cGVHD.
DFS was similar in all groups andOS worsewith aGVHD1 cGVHD. After MAC, GVHD has an adverse effect
on TRM with early modest augmentation of GVHD-associated graft-versus-leukemia (GVL). With RIC,
GVHD-associated GVL may be important in limiting both early and late leukemia recurrence.
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Graft-versus-host disease (GVHD) can comp-
licate allogeneic hematopoietic cell transplant
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oi.org/10.1016/j.bbmt.2012.06.014however, be associated with augmented antineoplastic
potency, thus limiting risks of relapse by this association
with the graft-versus-leukemia (GVL) effect [1,2].
The net impact on survival represents a differential
in potency between these 2 parallel immunologic
influences. In recent years, as older patients, or those
with pre-HCT comorbidities, receive allografts after
reduced-intensity conditioning (RIC), the strength of
the GVL effect has become more critical in limiting
the hazards of relapse. Because older patients may
also be more vulnerable to acute GVHD (aGVHD)
and/or chronic GVHD, we studied the effect of
GVHD on relapse, TRM, disease-free survival (DFS),
and overall survival (OS) after allogeneicHCT for acute
myelogenous leukemia (AML) and myelodysplastic
syndrome (MDS). The study goal was to identify any
differential GVHD-associated GVL influences after
transplantations using either myeloablative condition-
ing (MAC) or RIC regimens. We report the impact of
these immunologic influences on mortality and relapse
in these 2 settings in which less potent antineoplastic
conditioning might allow persistence of more minimal
residual disease and render the need for extra GVL
more critical for survival.1727
Table 1. Demographics of Patients Receiving Allogeneic HCT for AML and MDS
MAC RIC
All Cases
(Time-Dependent
Analysis cohort)
n 5 4022
Disease-Free
Survivors >1 Year
(Landmark Study
Cohort)
n 5 1739
Died, Relapsed,
or Follow-up #1 Year
(Excluded)
n 5 2283
All Cases
(Time-Dependent
Analysis Cohort)
n 5 1719
Disease-Free
Survivors >1 Year
(Landmark Study
Cohort)
n 5 630
Died, Relapsed,
or Follow-up #1 Year
(Excluded)
n 5 1089
Age, median year
(range)
42 (16-70) 41 (16-66) 43 (16-70) 56 (18-70) 56 (18-70) 56 (19-70)
Male, N (%) 2160 (54%) 927 (53%) 1233 (54%) 1004 (58%) 363 (58%) 641 (59%)
Disease
AML 2973 (74%) 1268 (73%) 1705 (75%) 1251 (73%) 451 (72%) 800 (73%)
MDS 1049 (26%) 471 (27%) 578 (25%) 468 (27%) 179 (28%) 289 (27%)
Disease stage*
Early 1328 (33%) 757 (44%) 571 (25%) 522 (30%) 225 (36%) 297 (27%)
Intermediate 648 (16%) 297 (17%) 351 (15%) 304 (18%) 126 (20%) 178 (16%)
Advanced 2004 (50%) 669 (38%) 1335 (58%) 864 (50%) 269 (43%) 595 (55%)
Unknown 42 (1%) 16 (1%) 26 (1%) 29 (2%) 10 (2%) 19 (2%)
HLA-matched sibling
donor
2650 (66%) 1189 (68%) 1461 (64%) 1027 (60%) 365 (58%) 662 (61%)
Unrelated donor 8/8
matched
1266 (31%) 515 (30%) 751 (33%) 631 (37%) 243 (39%) 388 (36%)
$1 loci mismatched 106 (3%) 35 (2%) 71 (3%) 61 (3%) 22 (3%) 39 (3%)
CMV + recipient 2363 (59%) 983 (57%) 1380 (60%) 1076 (63%) 401 (64%) 675 (62%)
CSA/Tac ± MTX 3536 (88%) 1556 (89%) 1980 (87%) 775 (45%) 298 (47%) 477 (44%)
CSA/Tac ± MMF 294 (7%) 112 (7%) 182 (8%) 730 (42%) 259 (41%) 471 (43%)
Ex vivo T cell
depletion
192 (5%) 71 (4%) 121 (5%) 214 (13%) 73 (12%) 141 (13%)
KPS, 90%-100% 2503 (62%) 1226 (71%) 1277 (56%) 924 (54%) 374 (59%) 550 (51%)
Year of HCT 2001 (97-06) 2001 (97-06) 2001 (97-06) 2003 (97-06) 2003 (97-06) 2003 (97-06)
aGVHD grade II to
IV, N (%)
1910 (47) 735 (42) 1175 (51) 754 (44) 274 (43) 480 (44)
CIF† at 5 years 48 (46%-49%) 42 (40%-45%) 52 (50%-54%) 44 (42%-46%) 44 (40%-47%) 44 (41%-47%)
cGVHD†, N (%) 1613 (40) 1148 (66) 465 (20) 683 (40) 458 (73) 225 (21)
CIF† at 5 years 42 (40%-43%) 67 (64%-69%) 22 (20%-23%) 43 (40%-45%) 75 (71%-79%) 23 (20%-25%)
MAC indicates myeloablative conditioning; RIC, reduced-intensity conditioning; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome;
CMV, cytomegalovirus; GVHD, graft-versus-host disease; CSA, cyclosporine A; Tac, tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil;
KPS, Karnofsky Performance Scale; HCT, hematopoietic cell transplant; aGVHD, acute graft-versus-host disease; CIF, cumulative incidence function;
cGVHD, chronic graft-versus-host disease.
Shown are the characteristics of all patients who underwent transplantation as well as those alive disease-free at 1 year included in the landmark analysis
and the excluded others.
*Early5AML in CR1 or refractory anemia; Intermediate5CR2-3; Advanced leukemia or RAEB (refractory anemiawith excess blasts), RAEB-T (trans-
formation).
†Cumulative incidence function (CIF; 95% confidence interval).
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Data Source
The Center for International Blood and Marrow
Transplant Research is a voluntary working group of
more than 450 transplantation centers worldwide
that contribute detailed data on consecutive allogeneic
and autologous HCT to a Statistical Center at the
Medical College of Wisconsin in Milwaukee and the
National Marrow Donor Program Coordinating Cen-
ter in Minneapolis, Minnesota. Participating centers
are required to report all transplantations consecu-
tively; compliance is monitored by on-site audits.
Patients are followed longitudinally. All patients pro-
vided written informed consent. The Institutional
Review Boards of the Medical College of Wisconsin
and the National Marrow Donor Program approved
this study.Inclusion Criteria
Patients with AML or MDS who received allo-
geneic HCT from 1997 to 2006 were eligible
(N 5 5741). Recipients of MAC and RIC regimens
were eligible, whereas children under 16 years were
excluded as were cases with ex vivo T cell–depleted
grafts. Transplantation regimens were defined as
reduced intensity for busulfan dose\9 mg/kg, mel-
phalan dose\150 mg/m2, and total body irradiation
dose #500 cGy.Outcomes
TRMwas defined as death not related to disease re-
currence or progression, and relapse was defined as dis-
ease recurrence based on morphological evaluation.
Patientswho received a second transplantation or donor
leukocyte infusion were censored at the time of event.
Table 2. Influence of GVHD on Outcome after HCT: Time-
Dependent Multivariate Analysis of All Patients
HR (95% CI) P Value
Relapse
MAC <.001*
No GVHD 1.00
aGVHD only 0.90 (0.78-1.04) .16
cGVHD only 0.68 (0.56-0.83) .0002
aGVHD + cGVHD 0.67 (0.55-0.82) <.0001
RIC <.0001*
No GVHD 1.00
aGVHD only 0.63 (0.51-0.77) <.0001
cGVHD only 0.53 (0.39-0.71) <.0001
aGVHD + cGVHD 0.39 (0.28-0.54) <.0001
TRM
MAC <.0001*
No GVHD 1.00
aGVHD only 2.51 (2.18-2.89) <.0001
cGVHD only 2.24 (1.78-2.81) <.0001
aGVHD + cGVHD 3.71 (3.03-4.54) <.0001
RIC <.0001*
No GVHD 1.00
aGVHD only 3.66 (2.88-4.65) <.0001
cGVHD only 2.10 (1.45-3.04) .0001
aGVHD + cGVHD 4.64 (3.37-6.40) <.0001
Treatment failure
MAC <.0001*
No GVHD 1.00
aGVHD only 1.52 (1.38-1.67) <.0001
cGVHD only 1.13 (0.98-1.32) .10
aGVHD + cGVHD 1.50 (1.31-1.72) <.0001
RIC .0007*
No GVHD 1.00
aGVHD only 1.25 (1.08-1.44) .003
cGVHD only 0.85 (0.67-1.07) .17
aGVHD + cGVHD 1.19 (0.96-1.47) .11
Survival
MAC <.0001*
No GVHD 1.00
aGVHD only 1.71 (1.55-1.89) <.0001
cGVHD only 0.99 (0.86-1.15) .90
aGVHD + cGVHD 1.37 (1.21-1.57) <.0001
RIC <.0001*
No GVHD 1.00
aGVHD only 1.52 (1.31-1.75) <.0001
cGVHD only 0.74 (0.60-0.92) .007
aGVHD + cGVHD 1.13 (0.93-1.37) .22
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell
transplant; MAC, myeloablative conditioning; HR, hazard ratio; CI, con-
fidence interval; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease; RIC, reduced-intensity conditioning;
TRM, treatment-related mortality.
For all HCT (MAC 4022; RIC 1719), shown are the hazard ratio (HR;
95% confidence intervals [CIs]) of the impact of aGVHD and/or cGVHD
on the incidence of relapse, nonrelapse treatment-related mortality
(TRM), treatment failure (relapse or death), and survival. Regression
models were adjusted as needed for age, performance status, diagnosis
and disease status, year of transplantation, and CMV serostatus.
All cases are included using the development of acute and/or chronic
GVHD as a time-dependent covariate.
*Three degree-of-freedom test.
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mission (CR). Treatment failure was defined as either
relapse or death from any cause—the inverse of DFS.
OS was calculated from the date of transplantation
with censoring at the time of last contact for survivors.
Statistical Analysis
The characteristics of patients, their disease, and
transplantation are shown in Table 1. Variables
related to patients, disease, and transplantation were
compared among the groups using the chi-square sta-
tistic. Occurrences of grade II to IV aGVHD and
cGVHD were based on reports from each trans-
plantation center. Patients were divided into 4 groups:
(1) those without GVHD, (2) those with aGVHD
alone, (3) those with cGVHD alone, and (4) those
with aGVHD and cGVHD. To examine the influence
of aGVHD and cGVHD on TRM, relapse, DFS,
and OS, we conducted 2 separate analyses, and all
analyses were performed separately for recipients of
MAC and RIC regimens. Cox regression models [3]
were built to adjust for effects of other patient, disease,
and treatment variables for both analyses. The first
analysis included all patients (N5 5791), and aGVHD
and cGVHD were treated as time-dependent cov-
ariates. The second analysis was a landmark analysis
that included patients who survived at least 1-year
disease-free after their transplantations (N 5 2369).
For the landmark analysis of 1-year disease-free survi-
vors, aGVHD and/or cGVHD status was evaluated at
1 year by which time all aGVHD and 95% of cGVHD
had developed. The landmark analysis allowed us to
examine any late effect of GVHD on those who were
disease-free for at least 1 year, whereas the analysis
with all patients allowed examination of any early ef-
fect of GVHD within 1 year. The results of multivar-
iate analysis are expressed as hazard ratio with the 95%
confidence interval. Factors considered in the multi-
variate models included age, gender, diagnosis, and
disease/remission status, donor type and HLA match-
ing, cytomegalovirus serostatus, performance status,
year of transplantation, and GVHD prophylaxis
along with the primarily analysis variables of
aGVHD and cGVHD. The probabilities of TRM
and relapse were calculated using cumulative incidence
[4-6]. In all analyses, data on patients without an event
were censored at last follow-up. Probability of DFS
and OS was calculated with the Kaplan-Meier esti-
mator [7]. Analyses used SAS version 9.2 (SAS Institute
Inc., Cary, NC).RESULTS
Patients
Details of patients’ demographics and disease
characteristics pretransplantation are shown, includ-ing all patients, the 1-year disease-free survivors in-
cluded in the landmark analysis, and those excluded
from the landmark analysis by death, relapse, or dura-
tion of follow-up \1 year, in Table 1. Forty-three
percent (1739 of 4022) of MAC transplantations and
37% (630 of 1719) of RIC recipients were alive and
disease-free at 1 year after HCT. The median time
to aGVHD onset after MAC was 23 days, and after
Table 3. Influence of GVHD on Outcome after HCT: Land-
mark Multivariate Analysis among 1-year Disease-Free Survi-
vors
Number HR (95% CI) P Value
Relapse
MAC
Disease-free survivors
at 1 year* (N 5 1739)
.9608†
No GVHD 511 1.00
aGVHD only 198 0.94 (0.60-1.46) .77
cGVHD only 524 0.95 (0.68-1.33) .75
aGVHD + cGVHD 506 0.91 (0.65-1.28) .60
RIC
Disease-free survivors
at 1 year* (N 5 630)
.0716†
No GVHD 130 1.00
aGVHD only 79 0.61 (0.28-1.32) .21
cGVHD only 228 0.72 (0.42-1.23) .23
aGVHD + cGVHD 193 0.44 (0.24-0.82) .009
TRM
MAC
Disease-free survivors
at 1 year* (N 5 1739)
<.0001†
No GVHD 511 1.00
aGVHD only 198 2.34 (1.32-4.15) .0038
cGVHD only 524 3.28 (2.08-5.18) <.0001
aGVHD + cGVHD 506 4.54 (2.92-7.04) <.0001
RIC
Disease-free survivors
at 1 year* (N 5 630)
.0009†
No GVHD 130 1.00
aGVHD only 79 1.24 (0.51-3.04) .64
cGVHD only 228 1.33 (0.68-2.60) .41
aGVHD + cGVHD 193 2.69 (1.44-5.04) .0020
Treatment failure
MAC
Disease-free survivors
at 1 year* (N 5 1739)
<.0001†
No GVHD 511 1.00
aGVHD only 198 1.30 (0.92-1.83) .13
cGVHD only 524 1.57 (1.21-2.04) .0006
aGVHD + cGVHD 506 1.83 (1.42-2.36) <.0001
RIC
Disease-free survivors
at 1 year* (N 5 630)
.3286†
No GVHD 130 1.00
aGVHD only 79 0.88 (0.49-1.57) .66
cGVHD only 228 0.91 (0.60-1.38) .67
aGVHD + cGVHD 193 1.23 (0.82-1.83) .32
Survival
MAC
Disease-free survivors
at 1 year* (N 5 1739)
<.0001†
No GVHD 511 1.00
aGVHD only 198 1.24 (0.85-1.82) .27
cGVHD only 524 1.74 (1.31-2.30) .0001
aGVHD + cGVHD 506 2.20 (1.68-2.87) <.0001
RIC
Disease-free survivors
at 1 year* (N 5 630)
.0277†
No GVHD 130 1.00
aGVHD only 79 0.99 (0.51-1.94) .98
cGVHD only 228 1.16 (0.72-1.86) .56
aGVHD + cGVHD 193 1.74 (1.10-2.76) .018
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell
transplant; HR, hazard ratio; CI, confidence interval; MAC, myeloabla-
tive conditioning; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease; RIC, reduced-intensity conditioning;
TRM, treatment-related mortality.
Shown are the HRs and 95% CIs of the impact of aGVHD and/or
cGVHD on the incidence of relapse, nonrelapse TRM, treatment failure
1730 Biol Blood Marrow Transplant 18:1727-1733, 2012D. Weisdorf et al.RIC was 28 days. The median times to cGVHD onset
were 4.7 months and 4.9 months after MAC and RIC
transplantations, respectively. Clinical characteristics
were similar across all groups, except that MAC recip-
ients were younger than those receiving RIC. Approx-
imately 75% of patients had AML and the remaining
had MDS. One-third of the patients were in first CR,
15% in second CR, and the remaining patients in
relapse at transplantation. Median follow-up was
4 years.
Relapse, TRM, and DFS: All Patients
Results of multivariate analysis of the entire cohort
with aGVHD1 cGVHDmodeled as time-dependent
covariates are shown in Table 2. Among recipients of
MAC transplantations, compared to patients without
GVHD, relapse risks were significantly lower in pa-
tients with cGVHD either alone or with aGVHD 1
cGVHD. Relapse risks were similar in patients with-
out GVHD or with only aGVHD. However, com-
pared to patients without GVHD, TRM was
significantly higher in patients with any GVHD. Con-
sequently, treatment failure and survival risks were sig-
nificantly higher in patients with aGVHD6 cGVHD.
Among recipients of RIC transplantations, com-
pared to patients without GVHD, patients with any
GVHD had significantly lower relapse risks. TRM
risks were also significantly higher in patients with
any GVHD. In contrast to the findings after MAC
transplantations after RIC, compared to patients with-
out GVHD, patients with aGVHD alone had signifi-
cantly more treatment failure. Treatment failure risks
were similar in patients without GVHD and those
with cGVHD with or without preceding aGVHD.
OS was worse in those with either aGVHD or
cGVHD.
Relapse, TRM, and DFS: Landmark Analysis
Multivariate analyses of the 1-year disease-free
survivor cohort are shown in Table 3. After MAC
transplantations, subsequent relapse risks among
1-year disease-free survivors were not significantly
different among all 4 GVHD groups (Figure 1A). In
contrast, TRM was higher in patients with
any GVHD (Figure 1B), leading to higher sub-
sequent treatment failure and lower DFS in those
with cGVHD and with aGVHD 1 cGVHD com-
pared to those with no GVHD (Figure 1C). Similarly,(relapse or death), and survival after MAC or RIC HCT. Regression
models were adjusted as needed for age, diagnosis and disease status,
GVHD prophylaxis, and year of transplantation.
*Three degree-of-freedom test.
†Fixed time effect of GVHD where acute and/or chronic GVHD status
were evaluated at 1 year after HCT.
Figure 1. The 5-year cumulative incidence of relapse in patients surviving disease-free at 1-year posttransplantation without graft-versus-host disease
(GVHD) (red —), with acute GVHD (aGVHD) (green - - -), with chronic GVHD (cGVHD) (blue – – –), and with aGVHD1 cGVHD (purple.) after
myeloablative conditioning (MAC) (A) or reduced-intensity conditioning (RIC) (D) transplantation. (F) The 5-year cumulative incidence of treatment-
related mortality (TRM) in patients surviving disease-free at 1-year posttransplantation without GVHD (red—), with aGVHD (green - - -), with cGVHD
(blue – – –), andwith aGVHD1 cGVHD (purple.) afterMAC (B) or RIC (E) transplantation. (G) The 5-year probability of disease-free survival (DFS) in
patients surviving disease-free at 1-year posttransplantation without GVHD (red —), with aGVHD (green - - -), with cGVHD (blue – – –), and with
aGVHD and cGVHD (purple .) after MAC (C) or RIC (F) transplantation. (H) The 5-year probability of survival in patients surviving disease-free
at 1-year posttransplantation without GVHD (red —), with aGVHD (green - - -), with cGVHD (blue – – –), and with aGVHD and cGVHD (purple
.) after MAC (D) or RIC (H) transplantation. Groups with statistically significant outcomes are marked with an bold orange arrow.
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cGVHD. After RIC transplantations, subsequent re-
lapse risks among 1-year disease-free survivors were
not significantly influenced by isolated aGVHD or
cGVHD, but risks were significantly lower in those
with both aGVHD and cGVHD (Figure 1D). TRM
(Figure 1E) was also higher only in those both
aGVHD and cGVHD. Consequently, treatment fail-
ure and DFS were similar in all groups (Figure 1F),
whereas survival was impaired only in those with
both aGVHD and cGVHD.DISCUSSION
The potency of allogeneic HCT in preventing
relapse has long been attributed to a T cell–mediated
antitumor effect targeting histocompatibility or
tumor-associated antigens expressed on the target
neoplastic cells [1,2,8]. A second contention that
GVHD was directly associated with the anti-
neoplastic effect was reported in a landmark article
that included only a modest number of patients with
leukemia [1]. In 1990, Horowitz et al. [2] described
1732 Biol Blood Marrow Transplant 18:1727-1733, 2012D. Weisdorf et al.a stepwise, more evident protection against relapse as-
sociated with aGVHD, cGVHD, or aGVHD 1
cGVHD. All transplantations with GVHD were
found to associate with more potent GVL than either
syngeneic or GVHD-free transplantation in a popula-
tion that included sibling donor MAC transplantation
for patients with AML, chronic myelogenous leuke-
mia, and acute lymphoblastic leukemia but not
MDS. Additionally, only a minority of patients in
that early report received double agent therapy for
posttransplantation immune suppression, which
might potentially alter the GVL effect. Despite these
differences, after MAC, the findings in the early study
are similar to the MAC transplantations in the current
study with a statistically significant GVL effect associ-
ated with aGVHD 1 cGVHD, but no significant ef-
fect of isolated aGVHD. However, no protection
against relapse had been seen with isolated cGVHD,
although only a few (n 5 54) patients were in that
group. In the current analysis, cGVHD alone or
with aGVHD was associated with relapse protection,
but only in the first posttransplantation year. In pa-
tients receiving RIC regimens, the situation is differ-
ent as both aGVHD and cGVHD, alone or in
combination, had protective effects on relapse.
The current analysis, by including a landmark
analysis of 1-year disease-free survivors, allowed us
to specifically examine later effects on relapse,
beyond 1 year. Here we observed further divergence
between GVHD and GVL with MAC and RIC
regimens. After MAC, we observed substantially
higher late TRM risks with any GVHD, but no
greater protection against relapse, suggesting that
any GVL effects have already been manifest in
the first year. GVHD, therefore, led to a substantially
higher risk of late treatment failure. In contrast,
among patients who had received RIC regimens,
1-year disease-free survivors with both aGVHD
and cGVHD continue to have a significant GVL
benefit, suggesting an ongoing active antileukemia
process. The increase in late TRM associated with
GVHD was restricted to patients with both aGVHD
and cGVHD and, although statistically significant,
was of a lesser magnitude in the cohort receiving
RIC versus MAC regimens. Consequently, there
was no higher risk of late treatment failure associated
with any GVHD in patients receiving RIC. These
data suggest that after RIC, a setting where late
GVHD-associated mortality is ameliorated, its
potent association with GVL might improve out-
comes and increase the fraction of patients with leu-
kemia who are surviving disease-free.
It is difficult to predict, however, the effect GVHD
on overall relapse and survival. Several recent reports
could not document augmented antineoplastic pro-
tection with either partially matched related or
unrelated donor transplantation compared toHLA-matched sibling transplantation—circumstances
where greater histoincompatibility leads to more
GVHD [9-12]. This suggests that the clinical
consequences of GVHD might not always be
accompanied by sufficiently potent GVL effects to
improve disease control and survival in patients with
AML or MDS. These observations do not illuminate
the mechanism underlying the immunologic
cytolytic effects that may be coordinately operative in
GVHD and GVL. T cell, natural killer cell, or
proapoptotic inflammatory responses may all limit
persistence of neoplastic cells, yet not induce
clinically uncontrollable or fatal GVHD [13-16].
What, therefore, are the clinical implications of these
findings? One might infer that using RIC [17-20],
in which a greater residual tumor burden may
persist after conditioning, clinically limited GVHD
and may convey a profound and important GVL
response. Indeed, in vivo T cell depletion using
antithymocyte globulin or alemtuzumab with RIC
transplantations has been reported to compromise
GVL and OS [21]. In patients with no manifestations
of GVHD, additional interventions including, for
example, adoptive cellular therapy or antitumor
vaccination might be warranted to limit the risks of
leukemia recurrence. Conversely, after MAC, with an
expectedly lower posttransplantation residual disease
burden, more stringent measures to limit GVHD
might be of net clinical benefit [22,23]. Clinical
strategies to balance these 2 effects, perhaps best
combined with measures to better detect persisting
posttransplantation minimal residual disease, might
be integrated to identify those most likely to benefit
from additional posttransplantation antileukemic
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